Terray Therapeutics rakes in $120M for AI-powered small-molecule drug development (October 22, 2024) by Kyt Dotson. Terray Therapeutics, a biotechnology company using artificial intelligence to accelerate the development of small-molecule drugs, said today it has raised $120 million in a Series B fundraising to enhance its AI platform. New investor Bedford Ridge Capital and existing
Forbion leads £35 million (c.$43 million) Series A financing in LoQus23 Therapeutics to advance its small molecule somatic expansion inhibition therapy for Huntington’s disease (October 2, 2024) in Portfolio News. Financing led by Forbion with participation from existing investors SV Health Investors’ Dementia Discovery Fund (DDF) and Novartis Venture Fund (NVF) Lead programme targeting MutSβ
